Description

Detralex Coated Tablets 1000 mg. №30

Ingredients

Detralex tablets contain 1000 mg of micronized purified flavonoid fraction (MPFF) composed of 90% diosmin and 10% hesperidin. The tablets also include excipients such as microcrystalline cellulose, gelatin, sodium lauryl sulfate, and talc.

Dosage

The recommended dosage of Detralex is usually one tablet taken twice daily, preferably during meals. The tablets should be swallowed whole with a sufficient amount of water.

Indications

Detralex is indicated for the treatment of symptoms related to chronic venous insufficiency, such as heavy legs, pain, and edema. It is also used in the management of acute hemorrhoidal attacks.

Contraindications

Detralex is contraindicated in individuals with known hypersensitivity to any of the ingredients. It should be used with caution in patients with severe hepatic impairment.

Directions

For optimal results, it is important to follow the directions provided by your healthcare provider. Detralex tablets are for oral use and should not be chewed.

Scientific Evidence

Detralex has been extensively studied for its efficacy in treating chronic venous insufficiency and hemorrhoids. Clinical trials have demonstrated that Detralex significantly improves symptoms such as leg pain, swelling, and cramps. Research published in the Journal of Vascular Research supports the use of MPFF in the management of venous disorders.

Additional Information

Detralex is well-tolerated, with mild side effects such as gastrointestinal disturbances reported infrequently. It is important to consult a healthcare professional before starting any new medication, especially if you have underlying medical conditions or are taking other medications concurrently.

Detralex works by improving venous tone, reducing venous distensibility, and protecting microcirculation. The flavonoids in Detralex act on the venous system, increasing venous tone and decreasing venous distensibility, which helps reduce symptoms associated with venous insufficiency.

Clinical trials have shown that Detralex is as effective as other venoactive drugs in improving symptoms of chronic venous insufficiency. A study published in the journal Angiology compared the efficacy of MPFF with other treatments and found similar improvements in symptoms across different interventions.